From Lab to Scale: How Irish Research Spin-Outs Are Creating 2,500+ Jobs While the Rest of Europe Talks About It
Ireland's research spin-out sector created over 2,500 jobs in a single recent reporting period. That is roughly the population of Carrick-on-Shannon, employed in companies that did not exist a decade ago, built on science that started in Irish lecture theatres.
The rest of Europe is still drafting the strategy documents.
The Gap Between Talking and Building
The European Commission has published more papers on innovation commercialisation than most Irish spin-outs have employees. The gap between research output and commercial reality across the EU is well documented: strong science, weak translation, almost no urgency. Ireland is moving in the opposite direction. Enterprise Ireland's knowledge transfer figures show a consistent pipeline of spin-outs progressing from proof-of-concept to paying customers to export revenue. The pipeline is not perfect. Many spin-outs stall at the funding bridge between seed and Series A. Some founder-researchers discover they are brilliant scientists and poor salespeople, and that is a hard truth to face in year three. But the ones that make it are building assets, not filing patents for the shelf.
The distinction matters. A patent on a shelf is a cost. A patent embedded in a product a German manufacturer is paying a licence fee for is a business. Ireland's best spin-outs have learned the difference and built accordingly.
Three Companies Actually Doing It
Akara Robotics, spun out of Trinity College Dublin's Robotics and Innovation Lab, built autonomous ultraviolet disinfection robots for hospitals. The founding team went from academic research into a sector, healthcare infection control, where the buyer's pain is acute and the cost of failure is visible. They did not discount to win early contracts. They priced on outcomes: reduced hospital-acquired infection rates, measurable in every ward. By 2023 they had won contracts in the UK and were in conversations with hospital networks in the Nordics. The team has grown to over 30 people, the majority based in Dublin. That is not a fundraising headline. That is a payroll.
PrecisionBiotics, originating from research at University College Cork, commercialised the science of the human microbiome before it became fashionable at wellness conferences. The founding insight was simple and hard to replicate: specific bacterial strains, identified through years of clinical research, produce measurable mental health and digestive outcomes. The company held that IP tightly, built a product called Zenflore, and got it onto pharmacy shelves across Europe. Revenue, not runway, became the metric. When it was acquired by Chr. Hansen, the Danish ingredients giant, Irish taxpayers got the upside on a decade of UCC-funded science. That is how knowledge transfer is supposed to work: public investment in research, private company built on the output, acquisition or scale creating a return that funds the next cycle.
Sigmoid Pharma, now part of Sublimity Therapeutics and spun from UCD, tackled one of the genuinely hard problems in drug delivery: getting medicines past the stomach to where they are needed in the gut. The science was deep, the market was real, and the team understood that the buyer in pharmaceutical licensing is not impressed by a pitch deck. They needed clinical data. They got it. The result was a platform technology that attracted Takeda, one of the world's largest pharmaceutical companies, as a partner on Crohn's disease treatment. A small Irish spin-out, licensed IP, to a global pharma operation. The jobs that creates, in clinical work, regulatory affairs, and manufacturing partnerships, are quiet and durable.
The Four-Stage Framework Irish Spin-Outs Use to Go From Lab to Export
The spin-outs that succeed follow a recognisable sequence. The ones that fail usually skip a step.
Step 1: Define the buyer before you refine the product. The founding researcher's instinct is to perfect the science. The commercial instinct is to find the person who will write the first cheque and work backwards from their problem. These are different activities and the order matters. Product refinement without a defined buyer produces beautiful technology that nobody buys.
Step 2: Price on value, not cost. University spin-outs often undervalue their IP because they are used to grant funding rather than commercial pricing. The research that became Zenflore took years and millions of euro. The price of the end product had to reflect that, or the business model never works. Cheap is not a strategy when your moat is deep science.
Step 3: Win one reference customer in a demanding market. A contract with a major NHS trust or a Tier 1 pharma partner is worth more than ten contracts with buyers who are not credible validators. The reference customer opens the next door. Akara understood this. One demanding, high-visibility hospital contract is a sales tool. Ten easy pilots in low-stakes environments are a comfort blanket.
Step 4: Build the team before the revenue demands it. Spin-outs that wait until they are overwhelmed before hiring commercial and regulatory talent lose twelve months they cannot recover. The knowledge transfer leaders who scale without burning out their teams are the ones who treat hiring as infrastructure, not as a reaction to crisis.
The Honest Picture
The 2,500 jobs figure is real and it matters, but it represents a fraction of what Ireland's research base could produce. Enterprise Ireland's support is genuine and the Knowledge Transfer Ireland office has made the licensing and spin-out process more navigable than it was a decade ago. The honest constraint is not funding at the early stage. Seed capital for Irish spin-outs is more available than it has ever been. The constraint is commercial leadership. Founding researchers who can also sell, or who recruit someone who can, are rare. The ones who crack it, as Ireland's innovation ecosystem continues to evolve, build companies that export science instead of importing jobs.
The Turn
Ireland's bet has always been on human capital over natural resources. The spin-out sector is the clearest expression of that bet paying off. Three companies, three different sectors, three different buyer types, and the same underlying logic: take something Ireland genuinely knows how to do at world level, build a business around it, and sell it to the world at a price that reflects its value.
That is a producer's posture. Europe's conference circuit is full of people who admire it. Ireland is the place where a small number of determined founders are actually living it.
